MONROVIA, Calif., Feb. 13, 2014 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA) a leading developer, manufacturer and marketer of minimally invasive ophthalmic products today reported the U.S. Food & Drug Administration's Ophthalmic Devices Panel of the Medical Devices Advisory Committee meeting scheduled for Friday, February 14, 2014 has been postponed due to weather.  The Agency has assured the Company that it intends to reschedule the meeting as soon as practically possible.  The meeting was being convened by the Agency to ask the Panel questions regarding STAAR's PMA supplement submission seeking approval to market the Company's Visian Toric Implantable Collamer® Lens.  Any rescheduled date will be published by the FDA on its website.

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive surgery as an alternative to LASIK is called an Implantable Collamer® Lens or "ICL." A lens used to replace the natural lens after cataract surgery is called an intraocular lens or "IOL." Over 400,000 Visian ICLs have been implanted to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 300 full time employees and markets lenses in over 60 countries. Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Aliso Viejo, CA; and Monrovia, CA. For more information, please visit the Company's website at www.staar.com. 

Collamer® is the registered trademark for STAAR's proprietary biocompatible collagen copolymer lens material.

SOURCE STAAR Surgical Company